Background/aims: Ulipristal acetate ([UPA], Esmya®) is an orally active selective progesterone-receptor modulator that has been approved as preoperative treatment for uterine myomas. This systematic review aims to summarize the available data on surgical outcomes of patients undergoing myomectomy by hysteroscopy or by laparoscopy after preoperative treatment with UPA. Methods: this review was performed following PRISMA guidelines and was registered in PROSPERO (CRD42018092201). PubMed, EMBASE, and Medline databases were systematically searched electronically until March 2018 for keywords concerning this topic. There were included only peer-reviewed, English language journal articles. Results: two prospective studies and 4 retrospective studies were included. The effect of UPA on the endometrium does not increase the technical difficulty during hysteroscopic myomectomy, but it increases the chance of complete primary resection in complex hysteroscopic myomectomies. Moreover, UPA does not increase the overall technical difficulty of laparoscopic myomectomy. Contradictory results have been reported on the impact of UPA on the separation of the myoma from the myometrium and on the consistency of the myomas. Conclusion: current results support the use of UPA prior to both surgical procedures. Further studies should confirm these preliminary findings and to assess the long-term outcomes of myomectomies following UPA treatment.

1.
Parker WH: Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 2007; 87: 725–736.
2.
Laganà AS, Vergara D, Favilli A, La Rosa VL, Tinelli A, Gerli S, Noventa M, Vitagliano A, Triolo O, Rapisarda AM, Vitale SG: Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynecological disease. Arch Gynecol Obstet 2017; 296: 855–867.
3.
Parker WH: Uterine myomas: management. Fertil Steril 2007; 88: 255–271.
4.
Xu Q, Takekida S, Ohara N, Chen W, Sitruk-Ware R, Johansson ED, Maruo T: Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005; 90: 953–961.
5.
Xu Q, Ohara N, Chen W, Liu J, Sasaki H, Morikawa A, Sitruk-Ware R, Johansson ED, Maruo T: Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006; 21: 2408–2416.
6.
Xu Q, Ohara N, Liu J, Amano M, Sitruk-Ware R, Yoshida S, Maruo T: Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14: 181–191.
7.
Cox J, Malik M, Britten J, Lewis T, Catherino WH: Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial. Reprod Sci 2018; 25: 198–206.
8.
Tafi E, Scala C, Leone Roberti Maggiore U, Bizzarri N, Candiani M, Venturini PL, Ferrero S: Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Expert Opin Drug Saf 2015; 14: 965–977.
9.
Ferrero S, Vellone VG, Barra F: Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol 2018; 14: 107–116.
10.
Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL I Study Group: Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409–420.
11.
Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E; PEARL II Study Group: Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421–432.
12.
Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, Barlow DH, Palacios S, Donnez O, Bestel E, Osterloh I, Loumaye E; PEARL III and PEARL III Extension Study Group: Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565–1573 e1561–1518.
13.
Fernandez H, Schmidt T, Powell M, Costa AP, Arriagada P, Thaler C: Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results. Eur J Obstet Gynecol Reprod Biol 2017; 208: 91–96.
14.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336–341.
15.
collaboration TC: Cochrane Handbook for Systematic Reviews of Interventions version 5.0.2, 2011.
16.
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programsclinical_epidemiology/-oxford.asp (accessed August 18, 2018).
17.
Bizzarri N, Ghirardi V, Remorgida V, Venturini PL, Ferrero S: Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. Eur J Obstet Gynecol Reprod Biol 2015; 192: 22–26.
18.
Murji A, Wais M, Lee S, Pham A, Tai M, Liu G: A multicenter study evaluating the effect of ulipristal acetate during myomectomy. J Minim Invasive Gynecol 2018; 25: 514–521.
19.
Ferrero S, Racca A, Tafi E, Alessandri F, Venturini PL, Leone Roberti Maggiore U: Ulipristal acetate before high complexity hysteroscopic myomectomy: a retrospective comparative study. J Minim Invasive Gynecol 2016; 23: 390–395.
20.
Sancho JM, Delgado VS, Valero MJ, Soteras MG, Amate VP, Carrascosa AA: Hysteroscopic myomectomy outcomes after 3-month treatment with either Ulipristal Acetate or GnRH analogues: a retrospective comparative study. Eur J Obstet Gynecol Reprod Biol 2016; 198: 127–130.
21.
Ferrero S, Alessandri F, Vellone VG, Venturini PL, Leone Roberti Maggiore U: Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. Eur J Obstet Gynecol Reprod Biol 2016; 205: 43–47.
22.
Luketic L, Shirreff L, Kives S, Liu G, El Sugy R, Leyland N, Solnik MJ, Murji A: Does ulipristal acetate affect surgical experience at laparoscopic myomectomy? J Minim Invasive Gynecol 2017; 24: 797–802.
23.
Munro MG, Critchley HO, Fraser IS; FIGO Menstrual Disorders Working Group: The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011; 95: 2204–2208, 2208 e2201–e2203.
24.
Lasmar RB, Barrozo PR, Dias R, Oliveira MA: Submucous myomas: a new presurgical classification to evaluate the viability of hysteroscopic surgical treatment – preliminary report. J Minim Invasive Gynecol 2005; 12: 308–311.
25.
Lasmar RB, Xinmei Z, Indman PD, Celeste RK, Di Spiezio Sardo A: Feasibility of a new system of classification of submucous myomas: a multicenter study. Fertil Steril 2011; 95: 2073–2077.
26.
Wamsteker K, Emanuel MH, de Kruif JH: Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol 1993; 82: 736–740.
27.
Wen L, Tseng JY, Wang PH: Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist. Taiwan J Obstet Gynecol 2006; 45: 173–175.
28.
Yu KJ, Lai CR, Sheu MH: Spontaneous expulsion of a uterine submucosal leiomyoma after administration of a gonadotropin-releasing hormone agonist. Eur J Obstet Gynecol Reprod Biol 2001; 96: 223–225.
29.
Kriplani A, Agarwal N, Parul D, Bhatla N, Saxena AK: Prolapsed leiomyoma with severe haemorrhage after GnRH analogue therapy. J Obstet Gynaecol 2002; 22: 449–451.
30.
Willame A, Marci R, Petignat P, Dubuisson J: Myoma migration: an unexpected “effect” with Ulipristal acetate treatment. Eur Rev Med Pharmacol Sci 2016; 20: 1439–1444.
31.
Chantraine F, Poismans G, Nwachuku J, Bestel E, Nisolle M: Expulsion of a uterine myoma in a patient treated with ulipristal acetate. Clin Case Rep 2015; 3: 240–242.
32.
Ferrero S, Scala C, Barra F: Regarding “Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy?”. J Minim Invasive Gynecol 2018; 25: 541.
33.
Zullo F, Pellicano M, Di Carlo C, De Stefano R, Marconi D, Zupi E: Ultrasonographic prediction of the efficacy of GnRH agonist therapy before laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 1998; 5: 361–366.
34.
Singh SS, Belland L, Leyland N, von Riedemann S, Murji A: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids. Am J Obstet Gynecol 2018; 218: 563–572.e1.
35.
Agency EM: Esmya: New Measures to Minimise Risk of Rare but Serious Liver Injury, 2018.
36.
Lethaby A, Puscasiu L, Vollenhoven B: Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev 2017; 11:CD000547.
37.
Vitale SG, Sapia F, Rapisarda AMC, Valenti G, Santangelo F, Rossetti D, Chiofalo B, Sarpietro G, La Rosa VL, Triolo O, Noventa M, Gizzo S, Lagana AS: Hysteroscopic morcellation of submucous myomas: a systematic review. Biomed Res Int 2017; 2017: 6848250.
38.
de Milliano I, Twisk M, Ket JC, Huirne JA, Hehenkamp WJ: Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: a systematic review and meta-analysis. PLoS One 2017; 12:e0186158.
39.
Lagana AS, Giacobbe V, Triolo O, Granese R, Ban Frangez H, Vrtacnik-Bokal E, Ietto C, Palmara VI: Dienogest as preoperative treatment of submucous myomas for hysteroscopic surgery: a prospective, randomized study. Gynecol Endocrinol 2016; 32: 408–411.
40.
Lagana AS, Palmara V, Granese R, Ciancimino L, Chiofalo B, Triolo O: Desogestrel versus danazol as preoperative treatment for hysteroscopic surgery: a prospective, randomized evaluation. Gynecol Endocrinol 2014; 30: 794–797.
41.
Lagana AS, Vitale SG, Muscia V, Rossetti P, Buscema M, Triolo O, Rapisarda AM, Giunta L, Palmara V, Granese R, Frangez HB, Romano A: Endometrial preparation with Dienogest before hysteroscopic surgery: a systematic review. Arch Gynecol Obstet 2017; 295: 661–667.
42.
Kadhel P, Smail M, Borja De Mozota D: Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma. J Gynecol Obstet Hum Reprod 2017; 46: 609–611.
43.
Istre O: Unexpected uterine leiomyosarcoma during laparoscopic hysterectomy treated 6 months with ulipristal acetate and contained power morcellation. J Minim Invasive Gynecol 2017; 24: 198.
44.
Ignatov T, Eggemann H, Dan Costa S, Ignatov A: Endometrial cancer after ulipristal acetate for uterine fibroma. Eur J Obstet Gynecol Reprod Biol 2017; 219: 134.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.